Clinical trials: Schizophrenia Patients
Psychosis
Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis
The purpose of this study is determine the minimal effective dose and the impact on: 1. treatment outcomes at 4, 12 and/or 48 weeks the treatment has required to treat patients experiencing the first psychotic episode 2.
- Trial name
- NCT00449397
- Testing
- Quetiapine Fumarate
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Mental Disorder, Depressive Disorder
Effects of Psychoeducation of Relatives to Patients With Serious Mental Illness
The purpose of this study is to determine the effects of psychoeducation for relatives to patients with serious mental illness.
- Conditions
- Mental Disorder, Depressive Disorder, Schizophrenia
- Trial name
- NCT00184379
- Testing
- Psychoeducation
- Where
- Norway
- Volunteers
- 50 people
- Sponsor
- Norwegian University of Science and Technology
Schizophrenia, Schizoaffective Disorder
Add-on HD Hf-tRNS Over Bilateral DLPFC for Treating Patients With Schizophrenia
The study aimed to investigate the effects of high-definition transcranial random noise stimulation over bilateral prefrontal cortex on psychopathological symptoms, other clinical outcomes, autonomic functioning ,and brain…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Symptoms, Neurocognitive Dysfunction
- Trial name
- NCT04038788
- Testing
- HD hf-tRNS
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Schizophrenia
Prucalopride for Cognitive Functioning in Schizophrenia
A core component of schizophrenia is neurocognitive impairment. The cognitive deficits are prominently seen in memory, attention, working memory, problem solving, processing speed and social cognition.
- Trial name
- NCT06474286
- Testing
- Prucalopride 1 MG
- Where
- India
- Volunteers
- 34 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Schizoaffective Disorder
Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin
This study supplements patients' current medications with Pravastatin, a cholesterol-lowering medication, to try to improve residual symptoms of schizophrenia, and also to improve cognitive functioning.
- Trial name
- NCT00177580
- Testing
- Pravastatin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Pittsburgh
Schizophrenia
An Exploratory Open Label Study of Adjunctive L-lysine Treatment in Patients With Schizophrenia
The objective of the present study was to investigate the possibility of using L-lysine, an amino acid that occurs naturally in food and which interferes with nitric oxide (NO) production, for the treatment of schizophrenia.
- Trial name
- NCT00996242
- Testing
- L-lysine
- Where
- Sweden
- Volunteers
- 10 people
- Sponsor
- Göteborg University
Schizophrenia, Cannabis Use Disorder
Impact of tDCS on Cannabis Craving in Schizophrenia
This study aims to evaluate the tDCS's impact on cannabis craving in patients with schizophrenia and cannabis addiction disorder.
- Trial name
- tCCS (NCT05784961)
- Testing
- tDCS
- Where
- 2 sites in France
- Volunteers
- 138 people
- Sponsor
- Centre hospitalier de Ville-Evrard, France
Schizophrenia
A Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia to Describe Medical Resource Utilization and Burden of Illness
This non-interventional, cross-sectional survey and retrospective review will evaluate the medical resource utilization and burden of illness in patients who have persistent symptoms of schizophrenia despite receiving adequately…
- Trial name
- NCT01959659
- Where
- 107 sites in Australia, Czechia and 5 more
- Volunteers
- 1,431 people
- Sponsor
- Hoffmann-La Roche
Mental Disorders, Schizophrenia
Web-Based Weight Management for Individuals With Mental Illness
Obesity and physical inactivity have become serious problems for individuals with mental illness, resulting in increased rates of chronic disease, premature death, and substantial health care costs.
- Conditions
- Mental Disorders, Schizophrenia, Affective Disorders, Psychotic, Overweight
- Trial name
- eWellness (NCT01324973)
- Testing
- eWellness
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, Los Angeles
Schizophrenia
Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia
Primary Objective: To evaluate the safety and tolerability of single doses of TV-44749 for subcutaneous (sc) use in Chinese participants with schizophrenia.
- Trial name
- NCT06253546
- Testing
- TV-44749 318mg, Oral Olanzapine 10mg/day, TV-44749 425mg
- Where
- 6 sites in China
- Volunteers
- 24 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Schizophrenia, Schizophreniform Disorder
Integrated Care in Psychotic Disorders With Severe Mental Illness
The study examine the effectiveness of an integrated care program including therapeutic assertive community treatment (ACT) for people with psychotic disorders fulfilling severe and persistent mental illness (SPMI, ACCESS-II…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder
- Trial name
- ACCESS-II (NCT01888627)
- Testing
- Integrated care
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Schizophrenia, Memory Disorders
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug Administration (FDA) approved for Attention Deficit…
- Conditions
- Schizophrenia, Memory Disorders, Cognition Disorders
- Trial name
- Atomoxetine (NCT00548327)
- Testing
- Atomoxetine, Functional magnetic resonance imaging, Neuropsychological Testing
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
A Study to Assess Learning Performance in Patients With Schizophrenia and Young and Elderly Healthy Volunteers
The purpose of this study is to measure and contrast implicit and explicit learning performance in patients with schizophrenia relative to young and elderly healthy volunteers.
- Trial name
- NCT01788436
- Testing
- Cognitive Test Battery 1, Cognitive Test Battery 2
- Where
- Belgium
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Severe Mental Disorder, Smoking Cessation
Tobacco Intensive Motivational and Estimate Risk
Randomized, open label, prospective study with a 12-month follow-up period. The primary objective evaluates the effectiveness of an intensive anti-smoking programme that informs patients of their individual risk of lung damages…
- Conditions
- Severe Mental Disorder, Smoking Cessation, COPD
- Trial name
- NCT03583203
- Testing
- personalized information about lung damage
- Where
- Spain
- Volunteers
- 230 people
- Sponsor
- Hospital Universitario Reina Sofia de Cordoba
Schizophrenia
Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia
This prospective, multi-center, 12 weeks naturalistic NIS trial will be conducted in 25 hospitals in naturalistic treatment setting.
- Trial name
- PLEASURE (NCT01160679)
- Where
- 12 sites in South Korea
- Volunteers
- 231 people
- Sponsor
- AstraZeneca
Psychotic Disorder
The Effectiveness of Forest Therapy on Psychotic Patients: Focusing on Changes in Inflammatory Pathways and The Psychotic Condition of Patients
General Formulation Are there any changes in the inflammatory pathway and psychotic conditions in patients given Forest Therapy compared to conventional psychotic disorder therapy? Specific Are there any differences in the levels…
- Trial name
- FT (NCT07436481)
- Testing
- Forest Therapy
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Natalia Dewi Wardani, MD
Prodromal Schizophrenia
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
Schizophrenia is a severe mental disorder associated with significant impairments in affective, cognitive and social functioning.
- Trial name
- ESPRIT-B1 (NCT03149107)
- Testing
- N-Acetylcysteine, IPPI (Integrated Preventive Psychological Intervention), PSM (Psychological stress management)
- Where
- 10 sites in Germany
- Volunteers
- 48 people
- Sponsor
- University Hospital, Bonn
Schizophrenia Patients
Effect of Ashwagandha as Adjunct Therapy on BDNF and Cognitive Function in Schizophrenia Patients
This study aims to evaluate the effectiveness of Ashwagandha (Withania somnifera) as an adjunctive therapy in improving serum brain-derived neurotrophic factor (BDNF) levels and cognitive function in patients with schizophrenia…
- Trial name
- ASH-BDNF (NCT07541157)
- Testing
- Risperidone 4mg/day, Ashwagandha
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Hasanuddin University
Schizophrenia
Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of 3 fixed doses of MP-214 orally administered once daily to patients with schizophrenia.
- Trial name
- NCT00862992
- Testing
- Cariprazine 3 mg, Cariprazine 6 mg, Cariprazine 12.5 mg
- Where
- Japan
- Volunteers
- 34 people
- Sponsor
- Tanabe Pharma Corporation
Severe Mental Illness, Rehabilitation
Using Clinical Process Indicators, Patient Reported Outcome Measures (PROMs), and Patient Reported Experience Measures (PREMs) to Improve the Quality and Continuity of Care for Psychiatric Patients
The objective of the proposed study is to take a further step in this direction by developing, implementing and monitoring a routine systematic evaluation of clinical process and outcome indicators, patient reported experience…
- Conditions
- Severe Mental Illness, Rehabilitation, Schizophrenia
- Trial name
- PROM-PREM (NCT04314154)
- Testing
- Monitoring PROM @ PREM data on participating patients
- Where
- Israel
- Volunteers
- 125 people
- Sponsor
- Shalvata Mental Health Center